# Preserve-Transplant Study

Study · id `cardio:ct-nct03102996` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03102996](<https://clinicaltrials.gov/study/NCT03102996>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03102996

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

## Technical summary

Registry record NCT03102996. Randomized; single masking; primary purpose treatment. Start 2017-06-12 (actual); primary completion 2021-06-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 240 participants (enrolled count; ClinicalTrials.gov record NCT03102996, source copy `cardio:ctgov-nct03102996-2022-04-22`, retrieved 2026-10-26)
- Started: 2017-06-12 (actual) (ClinicalTrials.gov record NCT03102996, source copy `cardio:ctgov-nct03102996-2022-04-22`, retrieved 2026-10-26)
- Primary completion: 2021-06-29 (actual) (ClinicalTrials.gov record NCT03102996, source copy `cardio:ctgov-nct03102996-2022-04-22`, retrieved 2026-10-26)
- Completion: 2021-07-26 (actual) (ClinicalTrials.gov record NCT03102996, source copy `cardio:ctgov-nct03102996-2022-04-22`, retrieved 2026-10-26)
- Countries: Switzerland (ClinicalTrials.gov record NCT03102996, source copy `cardio:ctgov-nct03102996-2022-04-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03102996-2022-04-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Preserve-Transplant Study
- Condition: Acidosis
- Condition: Renal Insufficiency
- Condition: Kidney Transplantation
- Intervention (Drug): Nephrotrans
- Intervention (Other): Placebo
- Lead sponsor: University of Zurich
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: University of Zurich (`cardio:org-university-of-zurich`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial (`cardio:pubmed-36708734`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2550f4d75004d8cd79a1a2c70456d92f87ea24a6ee180cbd397bd00eea9721d8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
